

In the Claims:

1-41. Cancelled.

42. (Currently amended) A method comprising evaluating the relative G protein receptor agonism, antagonism or inactivity of a compound for a G protein coupled receptor (GPCR) in a single sample by a flow cytometric process comprising the steps of (a) providing a sample suspension containing a detectable GPCR, a set of G protein beads which will form a ternary complex with said detectable GPCR in the presence of an agonist or partial agonist, and a set of ligand beads which will bind to said detectable GPCR, said set of G-protein beads comprising epitope-recognizing beads having an epitope bearing heterotrimeric G protein bound thereto and wherein at least one of said set of G protein beads and said set of ligand beads are detectable colored beads; (b) mixing said sample suspension with said compound; and (c) detecting the formation or absence of formation of a complex between said compound and said detectable GPCR, wherein a GPCR antagonist prevents binding of said detectable GPCR to said G protein beads by preventing ternary complex formation and prevents binding of said detectable GPCR to said ligand bead; a GPCR agonist allows binding of said detectable GPCR to said G protein beads by forming a ternary complex but prevents binding of said detectable GPCR to said ligand bead; and an inactive compound prevents binding of said detectable GPCR to said G protein beads by not promoting ternary complex formation but allows binding of said detectable GPCR to said ligand bead.

43. (Original) A method of claim 42, wherein the G protein coupled receptor is a β 2-adrenergic receptor containing a fluorescent moiety.

44. (Currently amended) A method of claim 42 43, wherein the fluorescent moiety is any a fluorescent protein fused to said G protein coupled receptor.

45. (Currently amended) A method of claim 43, wherein the detectable β 2-adrenergic receptor containing a fluorescent moiety is a β 2AR-Green Fluorescent Protein (GFP) fusion protein.

46. (Original) The method of claim 42 wherein said G protein beads are modified with a fluorescent moiety.

47. (Currently amended) The method of claim 46 wherein said fluorescent moiety is Texas Red a sulforhodamine 101 fluorescent moiety.

48-55. Cancelled.

The following claims are new:

56. (New) The method according to claim 42 wherein said ligand beads are modified with a fluorescent moiety.

57. (New) The method according to claim 42 wherein said G protein beads and said ligand beads are modified with a fluorescent moiety.